Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TYK MedicinesHKSE:02410 -4.08%7 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, TYK Medicines ranks worse than 106269.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TYK Medicines's EBITDA for the
six
months ended in Dec. 2025 was HK$-190.01 Mil. TYK Medicines's Revenue for the
six
months ended in Dec. 2025 was HK$0.00 Mil. Therefore, TYK Medicines's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TYK Medicines EBITDA Margin % Related Terms
TYK Medicines EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TYK Medicines's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02410 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, TYK Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TYK Medicines EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TYK Medicines's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TYK Medicines's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYK Medicines (HKSE:02410) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TYK Medicines and its competitors. According to the industry distribution chart, TYK Medicines ranks #999999 out of 941 companies in the Biotechnology industry.
Is TYK Medicines' EBITDA Margin % too high?
TYK Medicines' current EBITDA Margin % is 0.00%. Based on the distribution chart, TYK Medicines ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TYK Medicines ranks #999999 out of 941 companies for EBITDA Margin %. This places TYK Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TYK Medicines and its competitors. TYK Medicines's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score
Get the complete analysis for HKSE:02410
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02410 has been successfully added to your 
